Search icone
Search and publish your papers

Indian pharmacy in global context and market survey of antioxidant, ofloxacin, cefixin and cefuroxime

Or download with : a doc exchange

About the author


About the document

Published date
documents in English
term papers
18 pages
0 times
Validated by
0 Comment
Rate this document
  1. Introduction
  2. The Indian pharmaceutical sector
    1. Advantages in India
  3. The growth scenario
  4. Steps to strengthen the industry
  5. Future prospects of the pharmaceutical industry in India
  6. Research and development in the pharmaceutical industry
  7. A study on Wockhardt
    1. Mission and business philosophy
    2. Wockhardt and international pharma
    3. Marketing division
    4. Tie ups with Wallis laboratory limited and CP pharmaceuticals limited - UK
  8. Overview of the research and development
  9. Financial overview of Wockhardt
  10. Research methodology and survey
  11. Conclusion
  12. Bibliography

The Indian Pharmaceutical Industry today is in the front rank of India's science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organized sector, the Indian Pharmacy Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously.

Playing a key role in promoting and sustaining development in the vital field of medicines, Indian Pharmacy Industry boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world.

The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control.

[...] The Indian Government's decision to allow 100 percent foreign direct investment into the drugs and pharmaceutical industry is expected to aid the growth of contract research in the country. Technology transfer to 100 percent Indian subsidiaries of MNCs is expected only in 2005. Indian pharmaceutical interests in making a mark on the global scene got a boost when Dr. Reddy's licensed two of its anti-diabetic molecules to Novo Nordisk and when Ranbaxy licensed its Novel Drug Delivery System (NDDS) of ciprofloxacin to Bayer. [...]

[...] Indian companies, in an effort to consolidate their position, will have to increasingly look at merger and acquisition options of either companies or products. This would help them to offset loss of new product options, improve their R&D efforts and improve distribution to penetrate markets. Research and development has always taken the back seat amongst Indian pharmaceutical companies. In order to stay competitive in the future, Indian companies will have to refocus and invest heavily in R&D. The Indian pharmaceutical industry also needs to take advantage of the recent advances in biotechnology and information technology. [...]

[...] LICENCING In licensing of innovative drugs and products for clinical development and exclusive marketing arrangements in India and related markets. * Recently Wockhardt has licensed a Hemostatic product from Daiichi Pharmaceutical Co., Japan. Licensing out for clinical development, marketing and distribution of our Recombinant Bio-pharmaceuticals and Peptides. Bayer AG and Wockhardt come together to market anti-diabetic drug - Acarbose. This is the first time Wockhardt and Bayer have come together for a co-marketing arrangement in India, in addition to being the first such arrangement for an anti-diabetic product in the country. [...]

Top sold for business strategy

International Business Strategy - Acer, Inc.: Taiwan's rampaging dragon

 Business & market   |  Business strategy   |  Case study   |  09/29/2010   |   .doc   |   8 pages

Nike's outsourcing strategy

 Business & market   |  Business strategy   |  Case study   |  01/27/2011   |   .doc   |   5 pages

Recent documents in business strategy category

A strategic perspective of the TNT Express acquisition by FedEx

 Business & market   |  Business strategy   |  Case study   |  01/09/2019   |   .doc   |   14 pages

Strategic analysis: LIDL FRANCE

 Business & market   |  Business strategy   |  Case study   |  08/13/2018   |   .doc   |   23 pages